Free tool
FAERS Monitor: Seasonique
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021840 or its brand name (Seasonique, Ethinyl Estradiol, Levonorgestrel). Reports on generic versions are filed under their own applications.
Reports
200
Serious
73
37% of reports
Hospitalization
23
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue15
- metrorrhagia14
- nausea11
- vaginal haemorrhage11
- headache10
- pain9
- drug ineffective8
- pruritus8
- rash8
- anxiety7
- product substitution issue7
- somnolence7
- vomiting7
- weight increased7
- depression6
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 23 |
| 2015 | 20 |
| 2016 | 42 |
| 2017 | 25 |
| 2018 | 14 |
| 2019 | 19 |
| 2020 | 13 |
| 2021 | 5 |
| 2022 | 8 |
| 2023 | 9 |
| 2024 | 5 |
| 2025 | 7 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,959 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| metrorrhagiaSignal | 14 | 86.4 | 52.1 | 1,098 |
| vaginal haemorrhageSignal | 11 | 26.7 | 15.0 | 247 |
| product substitution issueSignal | 7 | 12.8 | 6.2 | 65 |
| somnolenceSignal | 7 | 3.7 | 1.8 | 11 |
| weight increasedSignal | 7 | 3.3 | 1.6 | 9 |
| depressionSignal | 6 | 2.8 | 1.3 | 5 |
| anxietySignal | 7 | 2.6 | 1.2 | 5 |
| pruritusSignal | 8 | 2.2 | 1.1 | 4 |
| fatigueSignal | 15 | 2.0 | 1.2 | 7 |
| rash | 8 | 1.9 | 1.0 | 3 |
| headache | 10 | 1.7 | 0.9 | 2 |
| vomiting | 7 | 1.6 | 0.8 | 1 |
| pain | 9 | 1.5 | 0.8 | 1 |
| nausea | 11 | 1.5 | 0.8 | 1 |
| drug ineffective | 8 | 0.6 | 0.3 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.